ReVision Optics initiates US clinical trial of PresbyLens corneal inlay

ReVision Optics, a leading company in the research, development and manufacture of custom optical products to correct and maintain vision, announced today that it has begun its US clinical trial of the PresbyLens® corneal inlay. The clinical trial will evaluate the PresbyLens® corneal inlay for the correction of presbyopia, the age-related loss of near vision. The study began on April 6th with the treatment of three subjects by clinical investigator Dr. Stephen Slade of the Slade & Baker Vision Center in Houston, Texas.

“We are pleased to begin our US clinical trials for the PresbyLens®. Our research and development studies strongly indicate that we may be able to provide a solution for one of the most common vision issues, presbyopia”

The PresbyLens® clinical study will evaluate 400 presbyopic subjects for three years. During the initial phase of enrollment, 30 eyes will be treated at two clinical sites. The first two investigators chosen are Dr. Stephen Slade of the Slade & Baker Vision Center in Houston, Texas, and Dr. Jon Dishler of the Dishler Laser Institute in Greenwood Village, Colorado.

Presbyopia is a common vision problem that affects everyone as they age. When people become older their eyes naturally lose the ability to focus, which typically happens around age 45. For people with good distance vision, symptoms of presbyopia can include difficulty seeing things close up like newspapers, menus and computer screens. Currently, more than 73 million people in the US are presbyopic.

ReVision Optics' PresbyLens® has the potential to gently reshape the cornea to improve a patient's near or reading vision. The lens is made from a proprietary, optically clear, biocompatible material that is similar to the material used in a soft contact lens.

"We are pleased to begin our US clinical trials for the PresbyLens®. Our research and development studies strongly indicate that we may be able to provide a solution for one of the most common vision issues, presbyopia," said J. Randy Alexander, President and CEO of ReVision Optics.

Source:

ReVision Optics™, Inc.,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Novel vaccine demonstrates high efficacy for prevention of COVID-19